BNTX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 1094 min ago

@ €88.56

Išleistas: 17 birž. 2024 @ 22:09

Grąža: -0.13%

Ankstesnis signalas: birž. 14 - 22:41

Ankstesnis signalas: Pirkimas

Grąža: -4.34 %

Live Chart Being Loaded With Signals

Commentary (17 birž. 2024 @ 23:00):
Our systems believe the stock currently is overvalued by -0.15% compare to its pairs and should correct downwards.

Stats
Šios dienos apimtis	1.12M
Vidutinė apimtis	735 393
Rinkos kapitalizacija	21.02B
EPS	€-1.310 ( Q1 \| 2024-05-06 )
Kita pelno data	( €-2.03 ) 2024-08-05
Last Dividend	€2.26 ( 2022-06-02 )
Next Dividend	€0 ( N/A )
P/E	173.41 (Sector) 42.63 (Industry) 24.32
ATR14	€3.99 (4.51%)

AADI -3.55%

ABCL -5.26%

ABCM 0.04%

ABEO -1.31%

ABIO -1.53%

ABOS -5.30%

ABSI -14.32%

ABUS -2.55%

ABVX -0.22%

ACAD -0.47%

ACER -17.95%

ACET -2.22%

ACGN 1.29%

ACHL 0.23%

ACHV 1.63%

ACIU -4.23%

ACLX -1.21%

ACRV -5.10%

ACST 0.62%

ACXP -0.42%

ADAG -5.64%

ADAP -7.23%

ADGI 0.87%

ADIL -2.29%

ADMA -1.79%

ADPT 0.32%

ADTX -7.69%

ADVM -3.94%

ADXN -6.11%

AEON 11.51%

AEZS -5.44%

AFMD -5.07%

AGEN -7.50%

AGIO -3.45%

AGLE 6.66%

AGTC 0.00%

AIKI 0.85%

AIMDW 53.45%

AKBA -1.87%

AKRO -4.46%

AKTX -6.33%

AKUS 0.00%

ALBO 0.00%

ALDX -1.34%

ALEC -2.35%

ALGS -5.76%

ALKS 2.08%

ALLK 0.86%

ALLO -2.13%

ALLR -3.01%

ALNA 3.16%

ALNY -1.93%

ALPN 0.00%

ALPX 0.00%

ALRN -0.31%

ALT -3.11%

ALVR -4.43%

ALXN 0.00%

ALXO -8.32%

ALZN -12.01%

AMRN -2.58%

AMTI -3.13%

ANAB -1.64%

ANEB -5.58%

ANGN 0.00%

ANIX -0.38%

ANL 0.61%

ANNX -4.63%

ANPC -3.15%

APGE -5.23%

APGN 8.48%

APGNW 30.65%

APLM -4.73%

APLS -3.98%

APLT -4.36%

APM 1.33%

APOP 0.38%

APRE 2.44%

APTO -3.96%

APTX 3.17%

APVO -20.53%

ARAV -13.39%

ARCT -9.26%

ARDS 20.48%

ARDX -0.94%

ARGX -2.25%

ARNA 0.00%

ARPO -0.90%

ARQT -7.76%

ARTL -0.38%

ARTLW 9.80%

ARVN -2.84%

ARWR -2.86%

ASLN -12.17%

ASMB -1.49%

ASND -2.39%

ATAI -2.19%

ATHA 2.36%

ATHE -1.61%

ATHX -33.50%

ATNF 15.09%

ATOS -4.17%

ATRA -16.93%

ATXI -1.66%

ATXS -3.50%

AUPH -1.95%

AURA 0.96%

AUTL -4.22%

AVBP -1.02%

AVEO 0.00%

AVIR -2.22%

AVRO 2.10%

AVTE -93.30%

AVTX 4.08%

AVXL -1.06%

AXLA 0.00%

AXSM 3.22%

AYLA 0.00%

AZRX 2.07%

BBI 2.17%

BBIO -2.26%

BCAB -1.89%

BCDA -2.05%

BCDAW -33.33%

BCEL -1.32%

BCLI -8.47%

BCRX 1.13%

BCTX 4.96%

BCTXW 0.00%

BCYC -4.33%

BDRX 1.89%

BDTX -8.38%

BEAM -3.38%

BFRA -2.91%

BGNE -1.97%

BIOR -10.12%

BIVI 0.41%

BLCM -6.68%

BLI -5.88%

BLPH -0.79%

BLRX -3.79%

BLTE -0.72%

BLU 0.03%

BLUE -0.77%

BMEA -9.75%

BMRN 1.81%

BNOX 1.64%

BNTC 2.46%

BNTX -3.95%

BOLD -5.95%

BOLT -0.82%

BPMC -1.59%

BPTH 10.65%

BPTS -13.47%

BRNS -6.63%

BRTX 20.00%

BTAI -2.92%

BTTX -7.50%

BTX 0.05%

BVXV 0.74%

BXRX 7.39%

BYSI 6.06%

CABA -12.20%

CADL -0.96%

CALA 60.00%

CALC -1.62%

CALT 0.03%

CAPR -4.06%

CARA -27.26%

CARM -9.65%

CASI -8.04%

CATB -6.97%

CBAY 0.03%

CBIO -2.65%

CBLI -7.31%

CBUS 3.07%

CCCC -5.48%

CCXI 0.00%

CDAK 0.00%

CDIO -1.51%

CDIOW -23.08%

CDMO 5.72%

CDMOP 0.04%

CDT -6.11%

CDTTW -47.71%

CDTX -6.32%

CDXC -0.67%

CDXS -2.30%

CELC -2.79%

CELU -2.19%

CELUW -9.52%

CERC -1.68%

CERE -0.16%

CERO -7.87%

CEROW -44.78%

CFRX -27.95%

CGEM 0.74%

CGEN -5.31%

CGON -2.68%

CGTX 0.92%

CHMA -6.00%

CHRS -2.96%

CINC 0.00%

CING -1.09%

CINGW -48.24%

CKPT -4.25%

CLBS -16.75%

CLDX 0.69%

CLGN 1.19%

CLLS -4.89%

CLNN -2.48%

CLNNW -41.25%

CLRB -9.94%

CLSD -0.84%

CLSN -0.68%

CLVS 0.00%

CMMB -24.79%

CMND 1.83%

CMPI 0.00%

CMPX 5.41%

CMRA 0.40%

CMRAW 33.33%

CMRX 1.44%

CNCE 0.00%

CNSP 3.94%

CNST 0.00%

CNTA -6.39%

CNTB 3.13%

CNTX -1.02%

COCP -0.16%

COEPW -0.66%

COGT 4.45%

CORT -1.31%

COYA -6.11%

CPRX -0.40%

CRBP -11.76%

CRBU -2.23%

CRDF -1.11%

CRGX -4.78%

CRIS 1.11%

CRNX -1.37%

CRSP -2.79%

CRTX 2.63%

CRVO -1.89%

CRVS -5.39%

CSBR 1.19%

CTCX -8.04%

CTIC 0.06%

CTMX -0.72%

CTNM 0.00%

CTXR -1.50%

CUE -1.47%

CVAC -5.18%

CVKD 3.18%

CWBR -2.55%

CYAD -12.96%

CYCC -3.55%

CYCCP -1.79%

CYCN 6.00%

CYT -2.27%

CYTK -2.13%

CYTO 2.48%

DARE -3.31%

DAWN -4.60%

DBTX -0.81%

DBVT 1.01%

DFFN 10.28%

DICE 0.06%

DMAC -0.42%

DNLI -1.21%

DNTH -2.85%

DOMH 1.99%

DRMA 0.00%

DRMAW 0.00%

DRNA 0.00%

DRTS -1.32%

DRTSW 1.01%

DRUG 0.00%

DSGN 2.97%

DTIL -2.07%

DYAI -5.29%

EARS -1.77%

EDIT 0.20%

EDSA 1.04%

EFTR -3.13%

EFTRW -0.26%

EIGR 0.00%

ELAB 1.44%

ELDN -6.93%

ELEV -7.89%

ELOX -12.50%

ELTX -2.33%

ELVN -0.65%

ELYM -13.05%

ENGN -3.89%

ENGNW -7.06%

ENLV -3.47%

ENOB 1.79%

ENSC -0.55%

ENTA -6.00%

ENTO -2.80%

ENTX 0.00%

ENVB -4.64%

EPIX -8.75%

EPRX -0.19%

EPZM 0.00%

EQ 0.50%

EQRX -2.09%

EQRXW 0.00%

ERAS -7.83%

ERNA 2.60%

ERYP 1.30%

ESLA -6.38%

ESLAW -9.25%

ETNB 1.03%

ETON -5.90%

ETTX 0.00%

EVAX -19.54%

EVGN -2.14%

EVLO 50.00%

EWTX -0.80%

EXAI 1.19%

EXEL 0.18%

EYEG -0.43%

EYEN 1.57%

EYPT -3.94%

FATE -1.11%

FBIO 1.60%

FBIOP -1.05%

FBLG -5.34%

FBRX -7.46%

FDMT 0.72%

FENC 0.74%

FGEN -5.36%

FHTX 9.52%

FIXX 0.77%

FMTX 0.00%

FNCH -6.25%

FOLD -0.99%

FREQ 4.76%

FRLN 0.15%

FRTX -0.54%

FSTX 0.00%

FTRE 0.38%

FULC -6.04%

FUSN 0.00%

FWBI 4.59%

FWP 0.00%

GALT -4.58%

GANX 6.45%

GBIO 6.57%

GBT 0.01%

GDTC 2.16%

GERN -4.11%

GHRS 3.42%

GLMD -6.66%

GLPG 1.18%

GLSI 18.16%

GLTO -4.90%

GLUE -4.18%

GLYC -9.70%

GMAB -1.57%

GMDA 0.00%

GMTX 0.00%

GNCA -85.71%

GNFT 0.14%

GNLX 1.27%

GNPX 1.84%

GNTA -0.60%

GOSS 0.02%

GOVX -7.50%

GOVXW -24.72%

GPCR 0.85%

GRAY -10.80%

GRCL 0.05%

GRNA -0.03%

GRNAW 8.91%

GRPH -2.75%

GRTS -2.71%

GRTX -4.26%

GTHX -3.96%

GUTS -3.90%

GXGXW 41.67%

GYRE 4.44%

HALO 0.32%

HARP 0.09%

HCWB -9.73%

HEPA -6.36%

HGEN -84.62%

HILS 5.66%

HLVX 1.33%

HOOK -4.04%

HOTH -3.73%

HOWL 3.99%

HRMY 1.10%

HRTX -10.42%

HSTO 62.16%

HUMA -12.20%

HUMAW -5.97%

IBRX -2.18%

ICCC 2.84%

ICPT 0.21%

ICU 1.30%

ICUCW -10.39%

ICVX -0.91%

IDRA -23.04%

IDYA -1.44%

IFRX -3.21%

IGMS 0.41%

IKNA -0.57%

IKT 8.90%

IMAB -1.09%

IMCR -3.82%

IMGN 0.02%

IMGO 0.00%

IMMP -0.74%

IMMX -0.49%

IMNM -11.86%

IMNN -1.80%

IMPL -27.27%

IMRA 15.96%

IMRN -2.78%

IMRX 1.66%

IMTX -0.08%

IMTXW -2.70%

IMUX -4.20%

IMV 0.00%

IMVT 3.08%

INAB -8.26%

INBX -9.62%

INCY 0.93%

INDP 7.98%

INFI -52.38%

INKT -1.05%

INM -2.58%

INMB -2.47%

INO -1.65%

INSM 1.22%

INTS -5.63%

INVA 1.57%

INZY -2.95%

IOBT -6.11%

IONS 0.27%

IOVA -0.98%

IPA 0.48%

IPHA -10.64%

IPSC 0.64%

IRON -3.05%

ISEE 0.38%

ITOS -6.04%

ITRM -1.74%

IVA -10.10%

IVVD -6.96%

JAGX -6.67%

JANX -4.57%

JAZZ 1.43%

JNCE 0.00%

JSPR -2.80%

JSPRW 2.33%

JUNS 0.00%

JUNSW 0%

KA 4.11%

KALV -2.07%

KDNY 0.22%

KMPH -0.34%

KNSA -1.28%

KNTE -0.38%

KOD -4.27%

KPRX -21.08%

KPTI 1.69%

KRBP 4.17%

KRON -3.70%

KROS -9.68%

KRRO -16.54%

KRTX 0.03%

KRYS -0.04%

KTRA -2.35%

KTTA -2.85%

KTTAW 8.62%

KURA -0.62%

KYMR -4.42%

KYTX -17.21%

KZIA -1.29%

KZR -2.71%

LABP 0.57%

LBPH 1.67%

LBPS 0.00%

LBPSW 14.81%

LEGN -2.24%

LENZ -0.54%

LEXX -5.18%

LEXXW -9.42%

LGND 0.72%

LGNDV 0.00%

LGVN -24.76%

LIAN 0.00%

LIFE 2.70%

LIPO -1.23%

LIXT 0.40%

LIXTW 27.74%

LJPC -0.32%

LMNL 0.12%

LOGC 2.76%

LPCN 12.64%

LPTX -1.90%

LQDA 3.01%

LRMR -14.91%

LSTA -4.97%

LTRN -8.57%

LUMO -2.95%

LVTX -9.52%

LXEO -6.50%

LXRX -5.49%

LYEL -8.05%

LYRA -8.37%

MACK 0.00%

MBIO 476.92%

MBRX -4.83%

MCRB -5.28%

MDGL -0.31%

MDNA -13.16%

MDWD 1.00%

MDXG 0.59%

MEIP 1.41%

MESO -0.55%

MGNX -4.03%

MGTA -7.74%

MGTX -2.23%

MGX -24.14%

MIRM 27.31%

MIRO 0.59%

MIST -1.42%

MITO 0.00%

MLEC -4.55%

MLECW 9.20%

MLND -5.36%

MLTX -2.99%

MLYS -3.02%

MNKD -1.04%

MNMD -3.36%

MNOV 0.00%

MNPR -8.51%

MOLN 8.81%

MOR 0.88%

MORF -1.25%

MREO 0.00%

MRKR 16.59%

MRNA -1.52%

MRNS -1.02%

MRSN -1.45%

MRTX -0.17%

MRUS -1.38%

MRVI -3.99%

MTCR -1.29%

MTEM 1.54%

MTP -18.50%

MURA 2.17%

MYMD 4.19%

NAMS -7.03%

NAMSW -7.61%

NAUT 0.00%

NBRV 0.71%

NBSE -1.56%

NBTX 4.77%

NCNA -1.64%

NERV 8.96%

NEXI 0.00%

NGM -1.28%

NGNE -6.08%

NKGN -4.44%

NKGNW 39.76%

NKTR 0.00%

NKTX -5.66%

NLSP 30.09%

NLSPW -16.67%

NMRA -4.09%

NMTR -42.97%

NOVN -24.84%

NRBO 0.45%

NRIX 0.72%

NRSN -3.82%

NRSNW 6.50%

NRXP 0.99%

NRXPW -15.65%

NRXS -6.06%

NTBL 13.82%

NTEC -12.45%

NTHI 0%

NTLA 0.08%

NTRBW -6.25%

NUVL -0.77%

NVAX -2.43%

NVCT 1.18%

NVIV -34.28%

NXTC -10.63%

NYMX -0.05%

OABI 0.95%

OABIW 13.46%

OBIO 0.88%

OBSV 0.00%

OCEA 10.64%

OCGN -5.63%

OCS -1.09%

OCUL -4.35%

OCUP 1.82%

ODT -4.27%

OKYO 0.00%

OLMA -3.96%

OMER -0.49%

OMGA -8.37%

ONCO 12.54%

ONCR -3.08%

ONCS 31.87%

ONCT -0.12%

ONCY -0.98%

ONTX -0.47%

ONVO 0.62%

OPNT 0.00%

OPT -5.51%

ORGS -1.72%

ORIC -0.67%

ORMP -0.44%

ORPH 0.00%

ORTX 0.30%

OSMT -1.77%

OTIC -92.64%

OTLK -1.43%

OVID -76.00%

OYST 0.00%

PALI 0.86%

PASG -3.81%

PBLA 9.76%

PBM -0.02%

PBYI 2.89%

PCSA 5.71%

PCVX -1.45%

PDSB -4.13%

PEPG 0.70%

PGEN 0.00%

PHAR 2.17%

PHAS 0.00%

PHAT 3.08%

PHIO 4.14%

PHIOW 36.47%

PHVS -0.53%

PHXM -5.20%

PIRS -5.64%

PKBO 0.00%

PKBOW 999 900.00%

PLRX -5.08%

PLUR 0.00%

PMN -5.59%

PMVP -1.20%

PNT 0.16%

PPBT -11.48%

PRAX -6.21%

PRDS 0.93%

PRLD 0.77%

PROG -3.47%

PROK 6.96%

PRQR -3.41%

PRTA -0.20%

PRTC -0.72%

PRTG -1.96%

PRTK 1.83%

PRVB 0.00%

PSTI -2.91%

PSTV 0.00%

PSTX 1.81%

PTCT -1.14%

PTE -0.82%

PTGX -2.76%

PTIXW 2.50%

PULM 3.72%

PXMD -1.92%

PYPD -0.36%

PYXS -3.43%

QLGN -11.72%

QNCX 0.00%

QNRX -10.97%

QSI -2.92%

QSIAW 0.00%

QTTB 3.82%

QURE -4.09%

RAIN -1.63%

RANI -5.46%

RAPT -0.30%

RARE 1.92%

RCKT -3.02%

REGN 0.85%

RENB -3.05%

REPL -6.63%

RETA 0.02%

REUN -0.89%

REVB 1.36%

REVBU 3.46%

REVBW 25.20%

RGLS -1.66%

RGNX -6.20%

RIGL -2.79%

RLAY -3.01%

RLMD -0.33%

RLYB -6.15%

RNA -0.10%

RNAC -14.55%

RNAZ -5.83%

RNXT 14.41%

ROIV 0.28%

ROIVW 4.56%

RPHM -0.60%

RPRX -1.15%

RPTX 0.00%

RUBY 2.70%

RVLP -32.05%

RVMD -3.94%

RVMDW -23.93%

RVNC -0.71%

RVPH -0.68%

RVPHW 11.54%

RXDX 0.09%

RXRX 1.19%

RYTM -3.76%

RYZB 0.02%

RZLT -2.53%

SABS 3.17%

SABSW -32.14%

SAGE -6.08%

SANA -1.32%

SAVA 0.81%

SAVAW 0.00%

SBBP 1.52%

SBTX 1.03%

SCNI 60.46%

SCPH -1.69%

SCPS 0.00%

SEEL -4.62%

SEER -3.37%

SELB -8.00%

SESN 7.29%

SGEN -0.07%

SGMO -17.30%

SGMT 1.93%

SGTX -2.56%

SIOX 22.63%

SLDB -5.44%

SLGL -2.22%

SLN -1.55%

SLNO 0.19%

SLRX 2.89%

SLS -16.67%

SMMT -5.84%

SNDX -1.14%

SNGX -5.91%

SNPX -3.97%

SONN -4.75%

SPPI -0.49%

SPRB 0.49%

SPRC -3.16%

SPRO -5.88%

SRNE 20.00%

SRPT -4.89%

SRRA 0.00%

SRRK -7.09%

SRZN -1.70%

STAB 0.00%

STOK -4.00%

STRO -7.51%

STSA 0.00%

STTK -19.55%

SURF -0.93%

SVRA -5.15%

SWTX -4.88%

SYBX -0.63%

SYRS -4.83%

TALS -0.73%

TARA -0.78%

TARS -6.91%

TBPH -0.59%

TCBP -8.64%

TCDA 0.00%

TCON 6.35%

TCRR 0.00%

TCRT 1.05%

TCRX -11.43%

TECH -1.40%

TENX -3.43%

TERN -2.93%

TFFP 0.52%

TGTX 0.12%

THRX 0.12%

TIL -2.06%

TLC 0.00%

TLSA 5.78%

TNGX 5.04%

TNXP -2.61%

TNYA -1.79%

TPST 0.34%

TRDA -3.61%

TRVI 2.08%

TRVN -1.88%

TSHA 1.51%

TSVT 3.29%

TTNP 1.45%

TVTX 2.23%

TYRA -8.69%

UBX -4.17%

UNCY 0.22%

URGN -4.79%

UTHR 3.12%

VACC 11.36%

VALN -1.55%

VAXX -0.11%

VBIV -3.61%

VBLT -8.77%

VCEL -1.37%

VCNX -3.70%

VCYT 1.96%

VERA -0.83%

VERU 2.29%

VERV -2.77%

VIGL -2.08%

VINC -4.90%

VIR -5.85%

VIRI 4.95%

VIRX -3.62%

VKTX 0.00%

VLON -13.04%

VNDA 1.76%

VOR 1.74%

VRCA 0.49%

VRDN -1.93%

VRNA 10.04%

VRPX 10.77%

VRTX -1.46%

VSTM 0.00%

VTGN -2.84%

VTVT -0.10%

VTYX -4.51%

VXRT -8.25%

VYGR -2.94%

VYNE 2.16%

VYNT 7.78%

WINT 7.98%

WVE -3.85%

XBIO 6.75%

XBIT -0.33%

XCUR -3.10%

XENE -1.75%

XERS -0.91%

XFOR -2.75%

XLO -6.86%

XLRN 0.00%

XNCR -5.15%

XOMA -4.31%

XOMAO 0.68%

XOMAP -0.14%

XRTX 1.96%

YMAB -1.34%

ZGNX 0.00%

ZIOP -0.88%

ZLAB 1.55%

ZNTL -5.09%

ZSAN 0.00%

Koreliacija (AI algo v.1.1b): Overvalued: -0.15% €88.60 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: 0.92 (very strong)

Trumpas: -0.93 (very strong negative)

Signal:(46) Neutral

BioNTech SE Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
OZEM	1
HPCO	0.949
KRSOX	0.919
OPTX	0.916
ATXS	0.91
UXIN	0.908
NUVO	0.906
NYXH	0.904
LDTC	0.904
CRGX	0.897

10 Labiausiai neigiamai susiję koreliacijos
INDH	-0.895
PPRUX	-0.876
ADSEW	-0.875
SFBC	-0.874
BOTT	-0.869
PSTR	-0.867
ELTX	-0.867
CCSB	-0.865
VCEL	-0.863
KRUS	-0.862

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

BioNTech SE Koreliacija - Valiuta/Žaliavos

-0.81
( strong negative )

-0.64
( weak negative )

0.58
( weak )

0.06
( neutral )

-0.17
( neutral )

0.71
( moderate )

BioNTech SE Finansinės ataskaitos

Annual	2023
Pajamos:	€3.82B
Bruto pelnas:	€3.22B (84.29 %)
EPS:	€3.79

FY	2023
Pajamos:	€3.82B
Bruto pelnas:	€3.22B (84.29 %)
EPS:	€3.79

FY	2022
Pajamos:	€17.31B
Bruto pelnas:	€12.78B (73.82 %)
EPS:	€38.08

FY	2021
Pajamos:	€18.98B
Bruto pelnas:	€15.12B (79.66 %)
EPS:	€40.63

Financial Reports:

No articles found.

BioNTech SE Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

BioNTech SE Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 7.79 - good (77.90%) | Divividend Growth Potential Score: 3.87 - No dividend growth expected in the near future

Information

First Dividend	€2.26	2022-06-02
Last Dividend	€2.26	2022-06-02
Next Dividend	€0	N/A
Payout Date	2022-06-17
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	€2.26	--
Avg. Dividend % Per Year	0.16%	--
Score	1.82	--
Div. Sustainability Score	7.79
Div.Growth Potential Score	3.87
Div. Directional Score	5.83	--

Next Divdend (Est)
(2024-06-18)

€0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

1.82

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2022	€2.26	0.98%
2023	€0	0.00%
2024	€0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
02 Jun 2022	€2.26	27 Apr 2022	03 Jun 2022	17 Jun 2022

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Diamond	2024-09-16	Monthly	14	15.03%	9.60
DMLP	Dividend Diamond	2024-04-26	Quarterly	22	10.71%	9.35
OXSQ	Dividend Diamond	2024-09-16	Monthly	21	12.73%	9.02
ARLP	Dividend Royal	2024-05-07	Quarterly	26	9.67%	8.87
PNNT	Dividend Royal	2024-06-14	Monthly	18	9.49%	8.82
MFIC	Dividend Royal	2024-06-11	Quarterly	21	10.89%	8.79
SPOK	Dividend Royal	2024-05-23	Quarterly	20	8.73%	8.72
PSEC	Dividend Royal	2024-06-25	Monthly	21	9.03%	8.65
SBLK	Dividend Royal	2024-06-06	Quarterly	17	13.10%	8.63
GBDC	Dividend Royal	2024-11-29	Bi-Monthly	15	8.53%	8.62

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0414	1.500	9.17	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00508	1.200	9.83	10.00	[0 - 0.3]
returnOnEquityTTM	0.00565	1.500	-1.048	-1.572	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	11.38	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	10.95	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	5.59	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0106	-1.500	9.82	-10.00	[0 - 0.6]
interestCoverageTTM	-17.52	1.000	-7.60	-7.60	[3 - 30]
operatingCashFlowPerShareTTM	23.83	2.00	2.06	4.11	[0 - 30]
freeCashFlowPerShareTTM	20.55	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.0118	-1.500	9.95	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.475	1.000	5.42	5.42	[0.2 - 0.8]
operatingProfitMarginTTM	-0.173	1.000	-5.45	-5.45	[0.1 - 0.6]
cashFlowToDebtRatioTTM	24.26	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.123	0.800	-2.52	-2.01	[0.5 - 2]
Total Score				7.79

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	194.23	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.00565	2.50	-0.674	-1.572	[0.1 - 1.5]
freeCashFlowPerShareTTM	20.55	2.00	3.15	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	23.83	2.00	2.06	4.11	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	7.43	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	2.10	1.000	10.00	0	[0.1 - 0.5]
Total Score				3.87

BioNTech SE Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.